Jefferies Financial Group Inc. Has $2.22 Million Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Jefferies Financial Group Inc. boosted its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 39.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 112,400 shares of the company's stock after purchasing an additional 31,800 shares during the period. Jefferies Financial Group Inc. owned 0.16% of Kiniksa Pharmaceuticals worth $2,223,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new stake in Kiniksa Pharmaceuticals during the third quarter valued at $4,997,000. SG Americas Securities LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $355,000. Charles Schwab Investment Management Inc. lifted its position in shares of Kiniksa Pharmaceuticals by 36.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company's stock worth $2,414,000 after buying an additional 32,393 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $3,955,000. Finally, Globeflex Capital L P lifted its position in shares of Kiniksa Pharmaceuticals by 217.1% in the fourth quarter. Globeflex Capital L P now owns 88,596 shares of the company's stock worth $1,752,000 after buying an additional 60,656 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Stock Performance

Shares of Kiniksa Pharmaceuticals stock traded up $0.38 during trading on Friday, reaching $26.25. The company's stock had a trading volume of 541,889 shares, compared to its average volume of 483,946. The business's fifty day moving average price is $22.86 and its 200-day moving average price is $21.36. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -187.49 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a one year low of $17.38 and a one year high of $28.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm's revenue for the quarter was up 72.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.25) earnings per share. Sell-side analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price target for the company. Wedbush reaffirmed an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Finally, Jefferies Financial Group boosted their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $38.80.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, insider Ross Moat sold 18,259 shares of the business's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $20.29, for a total transaction of $370,475.11. Following the transaction, the insider now directly owns 9,415 shares in the company, valued at $191,030.35. The trade was a 65.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Sanj K. Patel sold 2,872 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $27.03, for a total value of $77,630.16. Following the transaction, the chief executive officer now owns 96,674 shares in the company, valued at $2,613,098.22. This represents a 2.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 231,640 shares of company stock worth $5,669,136. Company insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.